Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material by Archana Jastorff, Arangassery Rosemary Bastian, Nynke Ligtenberg, Vladislav Klyashtornyy, Benoît Callendret, Esther Heijnen

Get full text

Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life by Tessa Hosman, Roy van Heesbeen, Arangassery Rosemary Bastian, Weihong Hu, Christy Comeaux, Nynke Ligtenberg, Bart van Montfort, Benoît Callendret, Esther Heijnen

Get full text

Adenovectored RSV prefusion glycoprotein + soluble glycoprotein combination immunization establishes persistent opsonophagocytic antibody response through IgG3 by Xin Tong, Ross Blanc, Deniz Cizmeci, Hadar Malca, Jaewon Kang, Christy Comeaux, Benoit Callendret, Arangassery Rosemary Bastian, Mehak Zahoor Khan, Galit Alter, Daniel Lingwood, Ryan P. McNamara, Ryan P. McNamara

Get full text